Zosano Pharma Corporation Company Profile (NASDAQ:ZSAN)

About Zosano Pharma Corporation

Zosano Pharma Corporation logoZosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZSAN
  • CUSIP:
Key Metrics:
  • Previous Close: $2.20
  • 50 Day Moving Average: $1.48
  • 200 Day Moving Average: $0.97
  • 52-Week Range: $0.45 - $3.54
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.59
  • P/E Growth: 0.00
  • Market Cap: $36.99M
  • Outstanding Shares: 16,815,000
  • Beta: 1.19
Profitability:
  • Return on Equity: -170.32%
  • Return on Assets: -82.84%
Debt:
  • Current Ratio: 2.38%
  • Quick Ratio: 2.38%
Additional Links:
Companies Related to Zosano Pharma Corporation:

Analyst Ratings

Consensus Ratings for Zosano Pharma Corporation (NASDAQ:ZSAN) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.00 (36.36% upside)

Analysts' Ratings History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Show:
DateFirmActionRatingPrice TargetDetails
2/14/2017Roth CapitalSet Price TargetBuy$2.00 -> $3.00View Rating Details
8/11/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Zosano Pharma Corporation (NASDAQ:ZSAN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
8/10/2016Q2($0.50)($0.54)ViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.68)ViewListenView Earnings Details
3/29/2016Q4($0.67)($0.64)ViewListenView Earnings Details
11/9/2015Q315($0.61)($0.72)$380.00 millionViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.63)$1.78 millionViewN/AView Earnings Details
3/25/2015($0.64)($1.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zosano Pharma Corporation (NASDAQ:ZSAN)
Current Year EPS Consensus Estimate: $-2.15 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.54)($0.54)($0.54)
Q2 20161($0.52)($0.52)($0.52)
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zosano Pharma Corporation (NASDAQ:ZSAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Insider Ownership Percentage: 5.37%
Institutional Ownership Percentage: 41.11%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/13/2017Enterprise Associates 12 NewMajor ShareholderSell1,099,996$2.01$2,210,991.96View SEC Filing  
9/16/2016Enterprise Associates 12 NewMajor ShareholderSell7,471$0.75$5,603.25View SEC Filing  
9/13/2016Enterprise Associates 12 NewMajor ShareholderSell10,000$0.74$7,400.00View SEC Filing  
8/29/2016M James BarrettMajor ShareholderSell50,000$1.01$50,500.00View SEC Filing  
8/24/2016Enterprise Associates 12 NewMajor ShareholderSell1,200$1.21$1,452.00View SEC Filing  
8/19/2016Donald J KellermanVPBuy15,920$1.32$21,014.40View SEC Filing  
8/19/2016Georgia ErbezCFOBuy47,750$1.32$63,030.00View SEC Filing  
8/19/2016John Peter WalkerDirectorBuy63,700$1.32$84,084.00View SEC Filing  
8/19/2016Konstantinos AlatarisCEOBuy127,389$1.32$168,153.48View SEC Filing  
7/21/2016Enterprise Associates 12 NewMajor ShareholderSell23,681$1.27$30,074.87View SEC Filing  
7/13/2016Enterprise Associates 12 NewMajor ShareholderSell13,382$1.20$16,058.40View SEC Filing  
1/30/2015Enterprise Associates 12 NewMajor ShareholderBuy23,457$11.00$258,027.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zosano Pharma Corporation (NASDAQ:ZSAN)
DateHeadline
News IconZosano Pharma Corp ZSAN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ZSAN)
www.bioportfolio.com - February 23 at 4:17 AM
News IconZosano Pharma Corporation's (ZSAN) stock price is Currently Worth at $3.12 (NASDAQ:ZSAN)
mundoaguaysaneamiento.net - February 21 at 4:22 PM
News IconZosano Pharma Corporation (NASDAQ:ZSAN) Reaches a New Pinnacle (NASDAQ:ZSAN)
www.graffiotech.com - February 15 at 7:06 AM
News IconInvestor's Healthcare Focused Stock: Zosano Pharma Corporation's (ZSAN) (NASDAQ:ZSAN)
mundoaguaysaneamiento.net - February 15 at 7:06 AM
insidermonkey.com logoZosano Pharma Corp (ZSAN) Is Playing With The Big Boys In The Migraine Space (NASDAQ:ZSAN)
www.insidermonkey.com - February 15 at 7:06 AM
benzinga.com logoHow Did Today's Zosano Pharma Short Call From Martin Shkreli Play Out? (NASDAQ:ZSAN)
www.benzinga.com - February 14 at 7:17 AM
streetinsider.com logoZosano Pharma (ZSAN) Says 3.8mg Dose of M207 Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine (NASDAQ:ZSAN)
www.streetinsider.com - February 14 at 7:17 AM
News IconZosano Pharma Corp. (NASDAQ:ZSAN) Surges on Positive Clinical Study Data for Migraine Patch (NASDAQ:ZSAN)
streetregister.com - February 14 at 7:17 AM
marketexclusive.com logoZosano Pharma Corp (NASDAQ:ZSAN) Is Playing With The Big Boys In The Migraine Space (NASDAQ:ZSAN)
marketexclusive.com - February 14 at 7:17 AM
finance.yahoo.com logoCan Zosano Pharma Turn Itself Around With This Late-Stage Migraine Trial Win? (NASDAQ:ZSAN)
finance.yahoo.com - February 14 at 7:17 AM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ZSAN)
biz.yahoo.com - February 14 at 7:17 AM
marketexclusive.com logoZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Other Events (NASDAQ:ZSAN)
marketexclusive.com - January 27 at 6:57 AM
4-traders.com logoZOSANO PHARMA CORP : Other Events (form 8-K) (NASDAQ:ZSAN)
www.4-traders.com - January 26 at 6:40 AM
4-traders.com logoZOSANO PHARMA CORP : Other Events (form 8-K) (NASDAQ:ZSAN)
www.4-traders.com - January 26 at 6:40 AM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Other Events (NASDAQ:ZSAN)
biz.yahoo.com - January 26 at 6:40 AM
4-traders.com logoZosano Pharma : Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:ZSAN)
www.4-traders.com - January 24 at 4:03 PM
finance.yahoo.com logoZosano Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:ZSAN)
finance.yahoo.com - January 24 at 5:46 AM
4-traders.com logoZosano Pharma : Zsan) Stake Maintained by Rosalind Advisors, Inc (NASDAQ:ZSAN)
www.4-traders.com - January 16 at 9:54 PM
publicnow.com logoZosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial (NASDAQ:ZSAN)
www.publicnow.com - January 6 at 6:47 AM
streetinsider.com logoZosano Pharma (ZSAN) Reports Sale of Non-Strategic Asset (NASDAQ:ZSAN)
www.streetinsider.com - November 23 at 8:50 PM
4-traders.com logoZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Regulation FD Disclosure (NASDAQ:ZSAN)
www.4-traders.com - November 23 at 8:50 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ZSAN)
biz.yahoo.com - November 22 at 8:46 PM
publicnow.com logoZosano Pharma Announces Sale of Non-Strategic Asset (NASDAQ:ZSAN)
www.publicnow.com - November 22 at 8:46 PM
seekingalpha.com logoNew owners take the reins at Zosano Pharma (NASDAQ:ZSAN)
seekingalpha.com - November 21 at 9:05 PM
finance.yahoo.com logoZOSANO PHARMA CORP Financials (NASDAQ:ZSAN)
finance.yahoo.com - November 17 at 8:10 PM
publicnow.com logoZosano Pharma Reports Third Quarter 2016 Financial Results (NASDAQ:ZSAN)
www.publicnow.com - November 9 at 8:45 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi (NASDAQ:ZSAN)
biz.yahoo.com - November 9 at 8:45 PM
streetinsider.com logoZosano Pharma (ZSAN) Completes Enrollment in Zotrip Trial (NASDAQ:ZSAN)
www.streetinsider.com - November 8 at 8:36 PM
publicnow.com logoZosano Pharma Announces Completion of Enrollment in Pivotal Efficacy Trial for M207 for Acute Migraine (NASDAQ:ZSAN)
www.publicnow.com - November 8 at 1:34 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ZSAN)
biz.yahoo.com - November 3 at 8:37 PM
openpr.com logoZosano Pharma Corp (NASDAQ:ZSAN) Investigation for Investors over possible Misconduct by certain directors (NASDAQ:ZSAN)
www.openpr.com - October 20 at 6:55 AM
4-traders.com logoZOSANO PHARMA CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) (NASDAQ:ZSAN)
www.4-traders.com - October 14 at 8:02 PM
biz.yahoo.com logoZOSANO PHARMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard (NASDAQ:ZSAN)
biz.yahoo.com - October 14 at 8:02 PM
News IconInvestor News: Certain directors of Zosano Pharma Corp (NASDAQ:ZSAN) faces Investigation (NASDAQ:ZSAN)
www.groundreport.com - October 12 at 8:18 PM
sbwire.com logoZosano Pharma Corp (NASDAQ:ZSAN) Investigation for Investors over Potential Misconduct by Certain Directors (NASDAQ:ZSAN)
www.sbwire.com - October 7 at 5:03 AM
finance.yahoo.com logoSHAREHOLDER NOTICE: Khang & Khang LLP Announces an Investigation of Zosano Pharma Corporation and Encourages Investors with Losses to Contact the Firm (NASDAQ:ZSAN)
finance.yahoo.com - October 6 at 5:14 AM
publicnow.com logoZosano Announces Inducement Grant for Georgia Erbez, Chief Business Officer (NASDAQ:ZSAN)
www.publicnow.com - September 9 at 7:52 PM
publicnow.com logoZosano Appoints Georgia Erbez as Chief Business Officer (NASDAQ:ZSAN)
www.publicnow.com - September 8 at 12:11 PM
News IconInvestor News: Investigation of Zosano Pharma Corp (NASDAQ:ZSAN) over potential Securities Laws Violations (NASDAQ:ZSAN)
www.groundreport.com - September 7 at 12:09 PM
sbwire.com logoInvestigation for Investors Who Lost Money by Investing in Shares of Zosano Pharma Corp (NASDAQ:ZSAN)
www.sbwire.com - September 1 at 8:14 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Zosano Pharma Corporation - ZSAN (NASDAQ:ZSAN)
finance.yahoo.com - September 1 at 11:39 AM
4-traders.com logoZosano Pharma Corp : Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Zosano Pharma Corporation (ZSAN) (NASDAQ:ZSAN)
www.4-traders.com - August 30 at 8:08 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation of Zosano Pharma Corporation (ZSAN) (NASDAQ:ZSAN)
finance.yahoo.com - August 29 at 8:21 PM
News IconIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Zosano Pharma Corp. & Advises Investors With Losses in... (NASDAQ:ZSAN)
ih.advfn.com - August 27 at 5:06 AM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Zosano Pharma Corporation and Advises Investors With Losses in Excess of $10,000 Contact the Firm (NASDAQ:ZSAN)
finance.yahoo.com - August 27 at 5:06 AM
finance.yahoo.com logoALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Zosano Pharma Corporation (NASDAQ:ZSAN)
finance.yahoo.com - August 26 at 7:59 PM
News IconDirector of Zosano Pharma Corporation (NASDAQ:ZSAN), Xanthopoulos Kleanthis G, buys 15,920 shares worth $21,014 (NASDAQ:ZSAN)
empowerednews.net - August 24 at 8:11 PM
finance.yahoo.com logoZosano Pharma Corp (ZSAN) President, CEO Konstantinos Alataris Bought $168,153 of Stocks (NASDAQ:ZSAN)
finance.yahoo.com - August 23 at 10:21 AM
streetinsider.com logoZosano Pharma (ZSAN) Prices Common Stock, Warrants Private Placement at $1.57/Unit (NASDAQ:ZSAN)
www.streetinsider.com - August 17 at 11:26 AM
finance.yahoo.com logo8:41 am Zosano Pharma enters securities purchase agreement to sell shares of its common stock and warrants to purchase shares of its common stock at a price of $1.57/unit in a private placement (NASDAQ:ZSAN)
finance.yahoo.com - August 16 at 11:47 AM

Social

What is Zosano Pharma Corporation's stock symbol?

Zosano Pharma Corporation trades on the NASDAQ under the ticker symbol "ZSAN."

Where is Zosano Pharma Corporation's stock going? Where will Zosano Pharma Corporation's stock price be in 2017?

2 brokerages have issued 1 year price objectives for Zosano Pharma Corporation's shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Zosano Pharma Corporation's stock price to reach $3.00 in the next year.

When will Zosano Pharma Corporation announce their earnings?

Zosano Pharma Corporation is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

Who owns Zosano Pharma Corporation stock?

Zosano Pharma Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include Amzak Capital Management, LLC (9.99%), FMR LLC (10.56%), Armistice Capital LLC (7.14%) and Eventide Asset Management LLC (1.62%). Company insiders that own Zosano Pharma Corporation stock include Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Konstantinos Alataris and M James Barrett.

Who sold Zosano Pharma Corporation stock? Who is selling Zosano Pharma Corporation stock?

Zosano Pharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC. Company insiders that have sold Zosano Pharma Corporation stock in the last year include Enterprise Associates 12 New and M James Barrett.

Who bought Zosano Pharma Corporation stock? Who is buying Zosano Pharma Corporation stock?

Zosano Pharma Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC. Company insiders that have bought Zosano Pharma Corporation stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker and Konstantinos Alataris.

How do I buy Zosano Pharma Corporation stock?

Shares of Zosano Pharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zosano Pharma Corporation stock cost?

One share of Zosano Pharma Corporation stock can currently be purchased for approximately $2.20.

Zosano Pharma Corporation (NASDAQ:ZSAN) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)

Earnings History Chart

Earnings by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)

Dividend History Chart

Dividend Payments by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)

Last Updated on 2/24/2017 by MarketBeat.com Staff